GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (FRA:7V3) » Definitions » Cyclically Adjusted PB Ratio

Cantargia AB (FRA:7V3) Cyclically Adjusted PB Ratio : 0.50 (As of May. 23, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Cantargia AB Cyclically Adjusted PB Ratio?

As of today (2025-05-23), Cantargia AB's current share price is €0.1192. Cantargia AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €0.24. Cantargia AB's Cyclically Adjusted PB Ratio for today is 0.50.

The historical rank and industry rank for Cantargia AB's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:7V3' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.51
Current: 0.51

During the past years, Cantargia AB's highest Cyclically Adjusted PB Ratio was 0.51. The lowest was 0.00. And the median was 0.00.

FRA:7V3's Cyclically Adjusted PB Ratio is ranked better than
71.21% of 667 companies
in the Biotechnology industry
Industry Median: 1.5 vs FRA:7V3: 0.51

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cantargia AB's adjusted book value per share data for the three months ended in Mar. 2025 was €0.026. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.24 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cantargia AB Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Cantargia AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantargia AB Cyclically Adjusted PB Ratio Chart

Cantargia AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1.12 0.54

Cantargia AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.07 1.40 1.05 0.54 0.47

Competitive Comparison of Cantargia AB's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Cantargia AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cantargia AB's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cantargia AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cantargia AB's Cyclically Adjusted PB Ratio falls into.


;
;

Cantargia AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Cantargia AB's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.1192/0.24
=0.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantargia AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Cantargia AB's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.026/132.8245*132.8245
=0.026

Current CPI (Mar. 2025) = 132.8245.

Cantargia AB Quarterly Data

Book Value per Share CPI Adj_Book
201506 0.225 99.995 0.299
201509 0.203 100.228 0.269
201512 0.149 100.276 0.197
201603 0.125 100.751 0.165
201606 0.201 101.019 0.264
201609 0.139 101.138 0.183
201612 0.116 102.022 0.151
201703 0.232 102.022 0.302
201706 0.186 102.752 0.240
201709 0.161 103.279 0.207
201712 0.439 103.793 0.562
201803 0.288 103.962 0.368
201806 0.250 104.875 0.317
201809 0.220 105.679 0.277
201812 0.190 105.912 0.238
201903 0.275 105.886 0.345
201906 0.220 106.742 0.274
201909 0.191 107.214 0.237
201912 0.155 107.766 0.191
202003 0.411 106.563 0.512
202006 0.394 107.498 0.487
202009 0.364 107.635 0.449
202012 0.728 108.296 0.893
202103 0.671 108.360 0.822
202106 0.606 108.928 0.739
202109 0.519 110.338 0.625
202112 0.431 112.486 0.509
202203 0.329 114.825 0.381
202206 0.255 118.384 0.286
202209 0.266 122.296 0.289
202212 0.212 126.365 0.223
202303 0.168 127.042 0.176
202306 0.133 129.407 0.137
202309 0.093 130.224 0.095
202312 0.082 131.912 0.083
202403 0.064 132.205 0.064
202406 0.044 132.716 0.044
202409 0.023 132.304 0.023
202412 0.055 132.987 0.055
202503 0.026 132.825 0.026

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cantargia AB  (FRA:7V3) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Cantargia AB Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Cantargia AB's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cantargia AB Business Description

Industry
Traded in Other Exchanges
Address
Scheelevagen 27, Lund, SWE, SE-223 63
Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.

Cantargia AB Headlines

No Headlines